Proteome Sciences Plc (PMSNF)
0.0248
0.00 (0.00%)
USD |
OTCM |
May 15, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 8.680M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -29.29% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 1.248 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 92.81% |
Profile
| Proteome Sciences Plc is a provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development. The company focuses on developing proprietary protein biomarkers for neurological diseases, oncology, and organ transplant rejection. Proteome Sciences was founded on December 10, 1993 and is headquartered in Cobham, the United Kingdom. |
| URL | http://www.proteome.co.uk |
| Investor Relations URL | N/A |
| HQ State/Province | Surrey |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Proteome Sciences Plc is a provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development. The company focuses on developing proprietary protein biomarkers for neurological diseases, oncology, and organ transplant rejection. Proteome Sciences was founded on December 10, 1993 and is headquartered in Cobham, the United Kingdom. |
| URL | http://www.proteome.co.uk |
| Investor Relations URL | N/A |
| HQ State/Province | Surrey |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |